nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

18.03.2021 | Review Article

Applicability, potential and limitations of TSPO PET imaging as a clinical immunopsychiatry biomarker

verfasst von: Livia J. De Picker, Benno C. M. Haarman

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

TSPO PET imaging may hold promise as a single-step diagnostic work-up for clinical immunopsychiatry. This review paper on the clinical applicability of TSPO PET for primary psychiatric disorders discusses if and why TSPO PET imaging might become the first clinical immunopsychiatry biomarker and the investment prerequisites and scientific advancements needed to accommodate this transition from bench to bedside.

Methods

We conducted a systematic search of the literature to identify clinical studies of TSPO PET imaging in patients with primary psychiatric disorders. We included both original case-control studies as well as longitudinal cohort studies of patients with a primary psychiatric diagnosis.

Results

Thirty-one original studies met our inclusion criteria. In the field of immunopsychiatry, TSPO PET has until now mostly been studied in schizophrenia and related psychotic disorders, and to a lesser extent in mood disorders and neurodevelopmental disorders. Quantitative TSPO PET appears most promising as a predictive biomarker for the transdiagnostic identification of subgroups or disease stages that could benefit from immunological treatments, or as a prognostic biomarker forecasting patients’ illness course. Current scanning protocols are still too unreliable, impractical and invasive for clinical use in symptomatic psychiatric patients.

Conclusion

TSPO PET imaging in its present form does not yet offer a sufficiently attractive cost-benefit ratio to become a clinical immunopsychiatry biomarker. Its translation to psychiatric clinical practice will depend on the prioritising of longitudinal research and the establishment of a uniform protocol rendering clinically meaningful TSPO uptake quantification at the shortest possible scan duration without arterial cannulation.

Savitz JB, Rauch SL, Drevets WC. Clinical application of brain imaging for the diagnosis of mood disorders: the current state of play. Mol Psychiatry. 2013;18:528–39. https://doi.org/10.1038/mp.2013.25.CrossRefPubMedPubMedCentral

Pariante CM. The year of immunopsychiatry: a special issue that foresaw the future. Psychoneuroendocrinology. 2019;103:49–51. https://doi.org/10.1016/j.psyneuen.2019.01.002.CrossRefPubMed

Hughes HK, Ashwood P. Overlapping evidence of innate immune dysfunction in psychotic and affective disorders. Brain, Behavior, & Immunity - Health. 2020;2. https://doi.org/10.1016/j.bbih.2020.100038.

van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64:820–2. https://doi.org/10.1016/j.biopsych.2008.04.025.CrossRefPubMed

Kim T, Pae AN. Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1). Expert Opin Ther Pat. 2016;26:1325–51. https://doi.org/10.1080/13543776.2016.1230606.CrossRefPubMed

Kim E, Howes OD, Kapur S. Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues Clin Neurosci. 2013;15:315–28.CrossRef

de Vries EF, Dierckx RA, Klein HC. Nuclear imaging of inflammation in neurologic and psychiatric disorders. Curr Clin Pharmacol. 2006;1:229–42.CrossRef

Banati R, Hickie IB. Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders. Med J Aust. 2009;190:S26–32.CrossRef

Craddock N, Owen MJ. The Kraepelinian dichotomy - going, going... but still not gone. The British journal of psychiatry : the journal of mental science. 2010;196:92–5. https://doi.org/10.1192/bjp.bp.109.073429.CrossRef

10.

Meyer JH, Cervenka S, Kim MJ, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry. 2020. https://doi.org/10.1016/S2215-0366(20)30255-8.

11.

Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR, et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study. Am J Psychiatry. 2016;173:44–52. https://doi.org/10.1176/appi.ajp.2015.14101358.CrossRefPubMed

12.

Collste K, Plaven-Sigray P, Fatouros-Bergman H, Victorsson P, Schain M, Forsberg A, et al. Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [(11)C]PBR28. Mol Psychiatry. 2017;22:850–6. https://doi.org/10.1038/mp.2016.247.CrossRefPubMed

13.

Conen S, Gregory CJ, Hinz R, Smallman R, Corsi-Zuelli F, Deakin B, et al. Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0829-y.

14.

Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M, et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry. 2016;6:e777. https://doi.org/10.1038/tp.2016.40.CrossRefPubMedPubMedCentral

15.

Di Biase MA, Zalesky A, O'Keefe G, Laskaris L, Baune BT, Weickert CS, et al. PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia. Transl Psychiatry. 2017;7:e1225. https://doi.org/10.1038/tp.2017.193.CrossRefPubMedPubMedCentral

16.

Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2009;50:1801–7. https://doi.org/10.2967/jnumed.109.066647.CrossRef

17.

Hafizi S, Tseng HH, Rao N, Selvanathan T, Kenk M, Bazinet RP, et al. Imaging microglial activation in untreated first-episode psychosis: a PET study with [(18)F]FEPPA. Am J Psychiatry. 2017;174:118–24. https://doi.org/10.1176/appi.ajp.2016.16020171.CrossRefPubMed

18.

Hafizi S, Da Silva T, Gerritsen C, Kiang M, Bagby RM, Prce I, et al. Imaging microglial activation in individuals at clinical high risk for psychosis: an in vivo PET study with [(18)F]FEPPA. Neuropsychopharmacology. 2017;42:2474–81. https://doi.org/10.1038/npp.2017.111.CrossRefPubMedPubMedCentral

19.

Holmes SE, Hinz R, Drake RJ, Gregory CJ, Conen S, Matthews JC, et al. In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [(11)C](R)-PK11195 positron emission tomography study. Mol Psychiatry. 2016;21:1672–9. https://doi.org/10.1038/mp.2016.180.CrossRefPubMed

20.

Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G, et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophr Bull. 2015;41:85–93. https://doi.org/10.1093/schbul/sbu157.CrossRefPubMed

21.

Laurikainen H, Vuorela A, Toivonen A, Reinert-Hartwall L, Trontti K, Lindgren M, et al. Elevated serum chemokine CCL22 levels in first-episode psychosis: associations with symptoms, peripheral immune state and in vivo brain glial cell function. Transl Psychiatry. 2020;10:94. https://doi.org/10.1038/s41398-020-0776-z.CrossRefPubMedPubMedCentral

22.

De Picker L, Ottoy J, Verhaeghe J, Deleye S, Wyffels L, Fransen E, et al. State-associated changes in longitudinal [(18)F]-PBR111 TSPO PET imaging of psychosis patients: evidence for the accelerated ageing hypothesis? Brain Behav Immun. 2019;77:46–54. https://doi.org/10.1016/j.bbi.2018.11.318.CrossRefPubMed

23.

Ottoy J, De Picker L, Verhaeghe J, Deleye S, Wyffels L, Kosten L, et al. (18)F-PBR111 PET imaging in healthy controls and schizophrenia: test-retest reproducibility and quantification of neuroinflammation. Journal of Nuclear Medicine. 2018;59:1267–74. https://doi.org/10.2967/jnumed.117.203315.CrossRefPubMed

24.

Takano A, Arakawa R, Ito H, Tateno A, Takahashi H, Matsumoto R, et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol. 2010;13:943–50. https://doi.org/10.1017/s1461145710000313.CrossRefPubMed

25.

van der Doef TF, de Witte LD, Sutterland AL, Jobse E, Yaqub M, Boellaard R, et al. In vivo (R)-[(11)C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis. NPJ Schizophr. 2016;2:16031. https://doi.org/10.1038/npjschz.2016.31.CrossRefPubMedPubMedCentral

26.

Plaven-Sigray P, Matheson GJ, Coughlin JM, Hafizi S, Laurikainen H, Ottoy J, et al. Meta-analysis of the glial marker TSPO in psychosis revisited: reconciling inconclusive findings of patient-control differences. Biol Psychiatry. 2020. https://doi.org/10.1016/j.biopsych.2020.05.028.

27.

De Picker L, Morrens M. Perspective: solving the heterogeneity conundrum of TSPO PET imaging in psychosis. Frontiers in Psychiatry. 2020;11:362. https://doi.org/10.3389/fpsyt.2020.00362.CrossRefPubMedPubMedCentral

28.

Marques TR, Ashok AH, Pillinger T, Veronese M, Turkheimer FE, Dazzan P, et al. Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. Psychol Med. 2019;49:2186–96. https://doi.org/10.1017/S0033291718003057.CrossRefPubMed

29.

Hannestad J, DellaGioia N, Gallezot JD, Lim K, Nabulsi N, Esterlis I, et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [(1)(1)C]PBR28 PET study. Brain Behav Immun. 2013;33:131–8. https://doi.org/10.1016/j.bbi.2013.06.010.CrossRefPubMedPubMedCentral

30.

Holmes SE, Hinz R, Conen S, Gregory CJ, Matthews JC, Anton-Rodriguez JM, et al. Elevated Translocator protein in anterior cingulate in major depression and a role for inflammation in suicidal thinking: a positron emission tomography study. Biol Psychiatry. 2018;83:61–9. https://doi.org/10.1016/j.biopsych.2017.08.005.CrossRefPubMed

31.

Li H, Sagar AP, Keri S. Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder. J Affect Disord. 2018;241:305–10. https://doi.org/10.1016/j.jad.2018.08.021.CrossRefPubMed

32.

Richards EM, Zanotti-Fregonara P, Fujita M, Newman L, Farmer C, Ballard ED, et al. PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Res. 2018;8:57. https://doi.org/10.1186/s13550-018-0401-9.CrossRefPubMedPubMedCentral

33.

Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72:268–75. https://doi.org/10.1001/jamapsychiatry.2014.2427.CrossRefPubMedPubMedCentral

34.

Setiawan E, Attwells S, Wilson AA, Mizrahi R, Rusjan PM, Miler L, et al. Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry. 2018;5:339–47. https://doi.org/10.1016/s2215-0366(18)30048-8.CrossRefPubMed

35.

Su L, Faluyi YO, Hong YT, Fryer TD, Mak E, Gabel S, et al. Neuroinflammatory and morphological changes in late-life depression: the NIMROD study. The British Journal of Psychiatry. 2016;209:525–6. https://doi.org/10.1192/bjp.bp.116.190165.CrossRefPubMedPubMedCentral

36.

Attwells S, Setiawan E, Rusjan PM, Xu C, Hutton C, Rafiei D, et al. Translocator protein distribution volume predicts reduction of symptoms during open-label trial of Celecoxib in major depressive disorder. Biol Psychiatry. 2020. https://doi.org/10.1016/j.biopsych.2020.03.007.

37.

Li H, Sagar AP, Keri S. Translocator protein (18kDa TSPO) binding, a marker of microglia, is reduced in major depression during cognitive-behavioral therapy. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;83:1–7. https://doi.org/10.1016/j.pnpbp.2017.12.011.CrossRef

38.

Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24–40. https://doi.org/10.1016/j.bbi.2019.06.015.CrossRefPubMed

39.

Haarman BC, Riemersma-Van der Lek RF, de Groot JC, Ruhe HG, Klein HC, Zandstra TE, et al. Neuroinflammation in bipolar disorder - A [(11)C]-(R)-PK11195 positron emission tomography study. Brain, Behavior, and Immunity. 2014;40:219–25. https://doi.org/10.1016/j.bbi.2014.03.016.CrossRefPubMed

40.

Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry. 2013;70:49–58. https://doi.org/10.1001/jamapsychiatry.2013.272.CrossRefPubMed

41.

Zürcher NR, Loggia ML, Mullett JE, Tseng C, Bhanot A, Richey L, et al. [(11)C]PBR28 MR-PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder. Molecular Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0682-z.

42.

Kumar A, Williams MT, Chugani HT. Evaluation of basal ganglia and thalamic inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection and Tourette syndrome: a positron emission tomographic (PET) study using 11C-[R]-PK11195. J Child Neurol. 2015;30:749–56. https://doi.org/10.1177/0883073814543303.CrossRefPubMed

43.

Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, et al. Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry. 2017;74:833–40. https://doi.org/10.1001/jamapsychiatry.2017.1567.CrossRefPubMedPubMedCentral

44.

Bhatt S, Hillmer AT, Girgenti MJ, Rusowicz A, Kapinos M, Nabulsi N, et al. PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studies. Nat Commun. 2020;11:2360. https://doi.org/10.1038/s41467-020-15930-5.CrossRefPubMedPubMedCentral

45.

De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22:485–502. https://doi.org/10.1016/s0197-2456(01)00153-2.CrossRefPubMed

46.

Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95. https://doi.org/10.1067/mcp.2001.113989.CrossRef

47.

Hamelin L, Lagarde J, Dorothee G, Potier MC, Corlier F, Kuhnast B, et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease. PloS one. 2018;141:1855–70. https://doi.org/10.1371/journal.pone.0195627.CrossRef

48.

Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer's disease trajectory. Brain. 2017;140:792–803. https://doi.org/10.1093/brain/aww349.CrossRefPubMedPubMedCentral

49.

Bunai T, Terada T, Kono S, Yokokura M, Yoshikawa E, Futatsubashi M, et al. Neuroinflammation following disease modifying therapy in multiple sclerosis: a pilot positron emission tomography study. J Neurol Sci. 2018;385:30–3. https://doi.org/10.1016/j.jns.2017.12.004.CrossRefPubMed

50.

Sucksdorff M, Rissanen E, Tuisku J, Nuutinen S, Paavilainen T, Rokka J, et al. Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017;58:1646–51. https://doi.org/10.3390/ijms18040785.CrossRef

51.

Datta G, Colasanti A, Rabiner EA, Gunn RN, Malik O, Ciccarelli O, et al. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain : a journal of neurology. 2017;140:2927–38. https://doi.org/10.1016/j.bbi.2017.10.013.CrossRef

52.

Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:277–86. https://doi.org/10.1016/j.pnpbp.2012.10.022.CrossRef

53.

Wolf SA, Boddeke HW, Kettenmann H. Microglia in physiology and disease. Annu Rev Physiol. 2017;79:619–43. https://doi.org/10.1146/annurev-physiol-022516-034406.CrossRefPubMed

54.

Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin G. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol. 2018;135:311–36. https://doi.org/10.1007/s00401-018-1815-1.CrossRefPubMedPubMedCentral

55.

Capuco A, Urits I, Hasoon J, Chun R, Gerald B, Wang JK, et al. Current perspectives on gut microbiome dysbiosis and depression. Adv Ther. 2020;37:1328–46. https://doi.org/10.1007/s12325-020-01272-7.CrossRefPubMedPubMedCentral

56.

van der Doef TF, Doorduin J, van Berckel BNM, Cervenka S. Assessing brain immune activation in psychiatric disorders: clinical and preclinical PET imaging studies of the 18-kDa translocator protein. Clinical and Translational Imaging. 2015;3:449–60. https://doi.org/10.1007/s40336-015-0140-0.CrossRefPubMedPubMedCentral

57.

Plaven-Sigray P, Matheson GJ, Collste K, Ashok AH, Coughlin JM, Howes OD, et al. Positron emission tomography studies of the glial cell marker translocator protein in patients with psychosis: a meta-analysis using individual participant data. Biol Psychiatry. 2018;84:433–42. https://doi.org/10.1016/j.biopsych.2018.02.1171.CrossRefPubMedPubMedCentral

58.

Plaven-Sigray P, Cervenka S. Meta-analytic studies of the glial cell marker TSPO in psychosis - a question of apples and pears? Psychol Med. 2019;49:1624–8. https://doi.org/10.1017/S003329171800421X.CrossRefPubMedPubMedCentral

59.

Sneeboer MAM, van der Doef T, Litjens M, Psy NBB, Melief J, Hol EM, et al. Microglial activation in schizophrenia: is translocator 18 kDa protein (TSPO) the right marker? Schizophr Res. 2020;215:167–72. https://doi.org/10.1016/j.schres.2019.10.045.CrossRefPubMed

60.

Downer OM, Marcus REG, Zurcher NR, Hooker JM. Tracing the history of the human translocator protein to recent neurodegenerative and psychiatric imaging. ACS Chem Neurosci. 2020;11:2192–200. https://doi.org/10.1021/acschemneuro.0c00362.CrossRefPubMed

61.

Betlazar C, Harrison-Brown M, Middleton RJ, Banati R, Liu GJ. Cellular sources and regional variations in the expression of the neuroinflammatory marker translocator protein (TSPO) in the normal brain. Int J Mol Sci. 2018;19. https://doi.org/10.3390/ijms19092707.

62.

Nutma E, Ceyzeriat K, Amor S, Tsartsalis S, Millet P, Owen DR, et al. Cellular sources of TSPO expression in healthy and diseased brain. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-020-05166-2.

63.

Pannell M, Economopoulos V, Wilson TC, Kersemans V, Isenegger PG, Larkin JR, et al. Imaging of translocator protein upregulation is selective for pro-inflammatory polarized astrocytes and microglia. Glia. 2020;68:280–97. https://doi.org/10.1002/glia.23716.CrossRefPubMed

64.

Turkheimer FE, Althubaity N, Schubert J, Nettis MA, Cousins O, Dima D, et al. Increased serum peripheral C-reactive protein is associated with reduced brain barriers permeability of TSPO radioligands in healthy volunteers and depressed patients: implications for inflammation and depression. Brain Behav Immun. 2021;91:487–97. https://doi.org/10.1016/j.bbi.2020.10.025.CrossRefPubMed

65.

Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev I, et al. Test-retest reproducibility of [(11)C]PBR28 binding to TSPO in healthy control subjects. Eur J Nucl Med Mol Imaging. 2016;43:173–83. https://doi.org/10.1007/s00259-015-3149-8.CrossRefPubMed

66.

Tuisku J, Plaven-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Bruck A, et al. Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [(11)C]PBR28 HRRT PET study. Eur J Nucl Med Mol Imaging. 2019;46:2329–38. https://doi.org/10.1007/s00259-019-04403-7.CrossRefPubMedPubMedCentral

67.

Danovich L, Veenman L, Leschiner S, Lahav M, Shuster V, Weizman A, et al. The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. European neuropsychopharmacology. 2008;18:24–33. https://doi.org/10.1016/j.euroneuro.2007.04.005.CrossRefPubMed

68.

May M, Slitzky M, Rostama B, Barlow D, Houseknecht KL. Antipsychotic-induced immune dysfunction: a consideration for COVID-19 risk. Brain Behav Immun Health. 2020;6:100097. https://doi.org/10.1016/j.bbih.2020.100097.CrossRefPubMedPubMedCentral

69.

Murru A, Manchia M, Hajek T, Nielsen RE, Rybakowski JK, Sani G, et al. Lithium's antiviral effects: a potential drug for CoViD-19 disease? Int J Bipolar Disord. 2020;8:21. https://doi.org/10.1186/s40345-020-00191-4.CrossRefPubMedPubMedCentral

70.

Hines CS, Fujita M, Zoghbi SS, Kim JS, Quezado Z, Herscovitch P, et al. Propofol decreases in vivo binding of 11C-PBR28 to translocator protein (18 kDa) in the human brain. Journal of Nuclear Medicine. 2013;54:64–9. https://doi.org/10.2967/jnumed.112.106872.CrossRefPubMed

71.

Smith CJ, Bhanot A, Norman E, Mullett JE, Bilbo SD, McDougle CJ, et al. A protocol for sedation free MRI and PET imaging in adults with autism spectrum disorder. J Autism Dev Disord. 2019;49:3036–44. https://doi.org/10.1007/s10803-019-04010-3.CrossRefPubMed

72.

Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. Journal of Cerebral Blood Flow and Metabolism. 2012;32:1–5. https://doi.org/10.1038/jcbfm.2011.147.CrossRefPubMed

73.

Attwells S, Setiawan E, Wilson AA, Rusjan PM, Miler L, Xu C, et al. Replicating predictive serum correlates of greater translocator protein distribution volume in brain. Neuropsychopharmacology. 2020;45:925–31. https://doi.org/10.1038/s41386-019-0561-y.CrossRefPubMed

74.

Nettis MA, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N, et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology. 2021. https://doi.org/10.1038/s41386-020-00948-6.

Titel: Applicability, potential and limitations of TSPO PET imaging as a clinical immunopsychiatry biomarker
verfasst von: Livia J. De Picker
Benno C. M. Haarman
Publikationsdatum: 18.03.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2021
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05308-0

Reduced microglia activity in patients with long-term immunosuppressive therapy after liver transplantation

Open Access
Original Article

Correction to: Global experience with PSMA‑based alpha therapy in prostate cancer

Correction

Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies

Open Access
Review Article

From radiotracer to radiopharmaceutical: a philosophical approach

Editorial

Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier

Original Article

[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial

Original Article

Springer Medizin

Applicability, potential and limitations of TSPO PET imaging as a clinical immunopsychiatry biomarker

Abstract

Purpose

Methods

Results

Conclusion

Weitere Artikel der Ausgabe 1/2021

Reduced microglia activity in patients with long-term immunosuppressive therapy after liver transplantation

Correction to: Global experience with PSMA‑based alpha therapy in prostate cancer

Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies

From radiotracer to radiopharmaceutical: a philosophical approach

Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier

[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Reduced microglia activity in patients with long-term immunosuppressive therapy after liver transplantation

Correction to: Global experience with PSMA‑based alpha therapy in prostate cancer

Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies

From radiotracer to radiopharmaceutical: a philosophical approach

Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier

[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial